Multinational drugmakers are returning to China’s centralized procurement program after rule changes gave originator medicines a second path to selection, though stronger price pressure still looms
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
A record 10 brand-name drugs won bids in China’s recently concluded 12th round of national centralized volume-based procurement, marking a shift in a program that multinational pharmaceutical companies have historically shunned due to steep price cuts.
The latest national drug tender seeks to curb destructive price competition while tightening quality requirements for generic…
The latest national drug tender seeks to curb destructive price competition while tightening quality requirements for generic…
Regulators have cited serious defects at more than 10 companies as Beijing tightens oversight of low-cost medicines and medical…
China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.
With more drugs in clinical trials than any other country, Chinese drugmakers are now shifting focus to the high-risk,…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
